Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

Ipilimumab has revolutionized malignant melanoma therapy, but a better understanding of the mechanisms behind treatment response and adverse effects is needed. In this work, the immune system of ipilimumab treated patients was monitored to investigate potential mechanisms of action that may correlat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: de Coaña, Yago Pico, Wolodarski, Maria, Poschke, Isabel, Yoshimoto, Yuya, Yang, Yuan, Nyström, Maria, Edbäck, Ulrika, Brage, Suzanne Eghyazi, Lundqvist, Andreas, Masucci, Giuseppe V., Hansson, Johan, Kiessling, Rolf
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400604/
https://ncbi.nlm.nih.gov/pubmed/28423487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15368
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak